Menu

Many Editors of US Medical Journals Receive Industry Funding

The authors of two new studies on the payments suggest stricter guidelines are needed.

Nov 8, 2017
Shawna Williams

ISTOCK, APPLEUZRRead through a paper in a reputable medical journal, and chances are that if its authors have a conflict of interest related to its contents—if they receive licensing payments for the technology described, for example, or research funding from industry—that information will be disclosed. But if the journal editor who decided to publish the paper has such a conflict of interest, that information is unlikely to be so easy to find.

In two studies published late last month in PeerJ (October 20) and The BMJ (October 26), researchers ran the names of editors of 35 (PeerJ) and 52 (BMJ) top US-based medical journals through the Open Payments database and found that the majority—63 percent of physician-editors in the PeerJ study, and just over half of higher-ranking editors in the BMJ study—had received industry payments in recent years.

STAT notes that in the BMJ report, the median take among the editors receiving industry funds in 2014 was just $11. However, two received more than $1 million each.

“[J]ournal editors are the ones who choose which manuscripts are sent out for peer review, who those peer reviewers are, and ultimately decide what gets published and what doesn’t. Because of their large role in shaping science, the biases of journal editors should be under closer scrutiny,” Victoria Wong, an author of the PeerJ study, tells Retraction Watch.

Wong adds, “The more funds that come from industry, the greater the likelihood that editorial decisions are not objective. It is unfortunate that we’re discussing the incomes of the very people who are the gatekeepers of the medical research that drives health care policy and expenditure, yet our current system does not think it important enough to provide them with a dedicated and unbiased source of income to do this job.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.